Literature DB >> 16410749

Deregulation of cdk5 in Hippocampal sclerosis.

Arjune Sen1, Maria Thom, Lillian Martinian, Tom Jacobs, Margareta Nikolic, Sanjay M Sisodiya.   

Abstract

Hippocampal sclerosis (HS) is the most common cause of chronic medically refractory epilepsy in adults. Histologically, HS is characterized by segmental neuronal loss and gliosis. Although neuronal loss is important to the pathophysiology of HS, the molecular mechanisms underlying the neuronal loss remain uncertain. Recently, it has been appreciated that proteins important in neurodevelopment may also have a role in neurodegeneration. Cyclin-dependent kinase 5 (cdk5), known to be crucial in development of the normal cerebral cortex, has now been shown as pivotal in several cell death paradigms, including apoptosis and necrosis. Deregulation of cdk5 by p25 causes hyperphosphorylation of tau and may contribute to pathology in several neurodegenerative conditions. Furthermore, it has been shown that after transient forebrain ischemia, cdk5 causes specific death of CA1 neurons in the rat hippocampus by direct phosphorylation of the NR2A subunit of the NMDA receptor and subsequent excitotoxicity. Because apoptosis, necrosis, and excitotoxicity are all thought to contribute to neuronal loss in HS, we hypothesized that abnormalities of the cdk5 pathway would accompany this disorder. Surgically resected cases of HS with adjacent histologically normal lateral temporal cortex were examined for cdk5 and its activator p35/p25. We consistently found increased immunoreactivity for p35/p25 in surviving neurons within areas of neuronal loss compared with areas where neurons were preserved. Western blots showed the ratio of p25 to p35 to be greater in diseased hippocampi than in the adjacent histologically normal temporal lobe. Histone-based kinase assays demonstrated increased activity of the p25-cdk5 complex in HS compared with the temporal lobe despite neuronal loss in the hippocampal samples. Our results suggest that p25 is pathologically increased in HS and that deregulation of cdk5 by p25 might contribute to neuronal death in this condition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410749     DOI: 10.1097/01.jnen.0000195940.48033.a2

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

1.  Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.

Authors:  David Muyllaert; Dick Terwel; Anna Kremer; Kristina Sennvik; Peter Borghgraef; Herman Devijver; Ilse Dewachter; Fred Van Leuven
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

2.  Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study.

Authors:  Maria Thom; Joan Y W Liu; Pam Thompson; Rahul Phadke; Marta Narkiewicz; Lillian Martinian; Derek Marsdon; Matthias Koepp; Luis Caboclo; Claudia B Catarino; Sanjay M Sisodiya
Journal:  Brain       Date:  2011-09-08       Impact factor: 13.501

3.  Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy.

Authors:  Long-Ze Sha; Xiao-Liang Xing; Dan Zhang; Yuan Yao; Wan-Chen Dou; Li-Ri Jin; Li-Wen Wu; Qi Xu
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 4.  Neuroprotective strategies against calpain-mediated neurodegeneration.

Authors:  Aysegul Yildiz-Unal; Sirin Korulu; Arzu Karabay
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-05       Impact factor: 2.570

Review 5.  Cognition and dementia in older patients with epilepsy.

Authors:  Arjune Sen; Valentina Capelli; Masud Husain
Journal:  Brain       Date:  2018-06-01       Impact factor: 13.501

6.  Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5.

Authors:  Ammar H Hawasli; Della Koovakkattu; Kanehiro Hayashi; Anne E Anderson; Craig M Powell; Christopher M Sinton; James A Bibb; Donald C Cooper
Journal:  PLoS One       Date:  2009-06-04       Impact factor: 3.240

7.  An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study.

Authors:  Arjune Sen; Mary Akinola; Xin You Tai; Mkael Symmonds; Gabriel Davis Jones; Sergio Mura; Joanne Galloway; Angela Hallam; Jane Y C Chan; Ivan Koychev; Chris Butler; John Geddes; Rohan Van Der Putt; Sian Thompson; Sanjay G Manohar; Eleni Frangou; Sharon Love; Rupert McShane; Masud Husain
Journal:  Trials       Date:  2021-07-31       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.